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Abstract: For many years the neuromodulator adenosine has been recognized as an endogenous anticonvulsant molecule 
and termed a “retaliatory metabolite.” As the core molecule of ATP, adenosine forms a unique link between cell energy 
and neuronal excitability. In parallel, a ketogenic (high-fat, low-carbohydrate) diet is a metabolic therapy that influences 
neuronal activity significantly, and ketogenic diets have been used successfully to treat medically-refractory epilepsy, par-
ticularly in children, for decades. To date the key neural mechanisms underlying the success of dietary therapy are un-
clear, hindering development of analogous pharmacological solutions. Similarly, adenosine receptor–based therapies for 
epilepsy and myriad other disorders remain elusive. In this review we explore the physiological regulation of adenosine as 
an anticonvulsant strategy and suggest a critical role for adenosine in the success of ketogenic diet therapy for epilepsy. 
While the current focus is on the regulation of adenosine, ketogenic metabolism and epilepsy, the therapeutic implications 
extend to acute and chronic neurological disorders as diverse as brain injury, inflammatory and neuropathic pain, autism 
and hyperdopaminergic disorders. Emerging evidence for broad clinical relevance of the metabolic regulation of adeno-
sine will be discussed. 
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INTRODUCTION 
  Adenosine  is  a  potent  neuromodulatory  purine  present 
throughout the extracellular space of the central nervous sys-
tem.  Adenosine  acts  at  pre-  and  postsynaptic  G  protein-
coupled receptor subtypes (A1, A2A, A2B, and A3) [58], and 
the influence of A1 and A2A receptor subtypes predominates 
due to their higher affinity for adenosine (~100 nM) [100] 
and their activation by ongoing levels of adenosine. In brain, 
A1 receptors are distributed widely [73] and A2A receptors 
are located preferentially in the basal ganglia and olfactory 
tubercle  [169].  Both  the  A1  and  A2  receptor  subtypes  are 
antagonized by caffeine, the most widely used psychoactive 
substance worldwide, and caffeine’s actions at adenosine A1 
and A2A receptors in the central nervous system underlie its 
alerting, locomotor and cognitive effects [136].  
  Adenosine exerts a tonic inhibition of neuronal excitabil-
ity via A1 receptors in many brain regions, including hippo-
campus and cerebral cortex, and this baseline inhibition in-
fluences both baseline synaptic activity [132, 175] and neu-
ronal  plasticity  [36].  Adenosine’s  inhibitory  influence  also 
alters seizure threshold directly, and increased extracellular 
adenosine during a seizure plays a key role in postictal de-
pression [193] and in keeping a seizure focus localized [140] 
via adenosine A1 receptors [74]. Large additional amounts of 
adenosine are mobilized during metabolically stressful cellu-
lar conditions such as low oxygen or glucose [57], and in-
creased  extracellular  adenosine  acting  at  the  adenosine A 1 
receptor has been shown to be neuroprotective during condi-
tions of metabolic stress [45]. Overall, adenosine holds well 
established and profound therapeutic potential for conditions 
such as stroke, brain injury, pain and epilepsy, among others 
[17, 79]. 
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  Whereas adenosine’s role as an endogenous neuroprotec-
tive molecule during pathology such as stroke, hypoxia and 
brain  injury  is  of  paramount  clinical  importance,  and  has 
long been the focus on adenosine-based therapies, the ongo-
ing effects of adenosine are critical to baseline neuronal ex-
citability and sleep behaviors. In addition, adenosine influ-
ences the risk for an epileptic seizure, and can control sig-
nificantly the expression and progression of a broad range of 
acute and chronic neurological conditions. With an unparal-
leled long-term epidemiological database based on manipu-
lating the influence of endogenous adenosine, i.e. the world-
wide consumption of caffeine [60, 85], a strategy focused on 
regulating endogenous adenosine is likely to be well toler-
ated and non-toxic.  
  To date, receptor-based strategies to augment the inhibi-
tory influence of adenosine by targeting A 1 receptors have 
been unable to harness its clinical potential, primarily due to 
peripheral  side  effects  [43,  51].  Accordingly,  interest  has 
intensified in the regulation of adenosine directly by physio-
logical stimulation [42, 45, 76, 77], metabolism [125] and 
adenosine  kinase  [75],  an  astrocytic  intracellular  enzyme 
that, together with equilibrative adenosine transport, controls 
extracellular adenosine levels. We now appreciate the active 
role of astrocytes in regulating extracellular adenosine [156], 
underscoring  the  multi-faceted  and  direct  impact  that  glia 
have on neuronal activity and signaling. Together, these re-
cent findings highlight the dynamic regulation of adenosine 
by cellular and metabolic stimuli, and thus expose new clini-
cally-relevant strategies for augmenting adenosine.  
ADENOSINE:  A  KEY  LINK  BETWEEN  METABO-
LISM AND NEURONAL SIGNALING 
  As both the core of ATP and a prevalent neuromodulator, 
adenosine is poised to link changes in cell metabolism with 
changes in neuronal activity [109]. Indeed, adenosine levels 
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metabolic  stress  and earned adenosine  the  apt  title of  “re-
taliatory metabolite” [138] - its profound inhibitory influence 
at both pre- and postsynaptic receptors serves to limit energy 
demand and excitotoxicity when energy availability is com-
promised [59]. The direct release of adenosine via nucleoside 
transporters  can  increase  extracellular  adenosine  under 
physiologically  stressful  conditions  [114],  and  typically 
adenosine’s role as a retaliatory metabolite is thought to be 
mobilized  when  intracellular  ATP  dephosphorylation  out-
strips ATP production [145, 170]. However, the regulation of 
adenosine by ongoing physiological stimuli and under non-
pathological conditions of adequate or even high intracellular 
ATP is becoming more appreciated [45, 96, 128]. In addi-
tion, degradation of extracellular ATP is a major source of 
extracellular  adenosine  [29,  44,  82],  so  manipulations  that 
increase extracellular ATP have a net effect on neuromodu-
lation by adenosine [44]. 
  Ketogenic strategies such as fasting or adhering to a ke-
togenic (high-fat, low-carbohydrate) diet increase ATP and 
other energy molecules in brain [20, 37, 126, 134]. These 
metabolic manipulations are known to reduce seizures sig-
nificantly [194], and have been shown to offer neuroprotec-
tion in animal models of brain injury [70, 125]. Emerging 
evidence  suggests  that  mimicking  key  cellular  aspects  of 
ketogenic metabolism increases extracellular adenosine [96], 
and furthermore, that an increased influence of adenosine at 
the A1 subtype plays a key role in the anticonvulsant success 
of  ketogenic  strategies  [127]  via  its  combined  presynaptic 
inhibition  of  glutamatergic  terminals  and  its  postsynaptic 
hyperpolarization  via K
+  channels.  Due  to  the  functional 
coupling  and  inverse  relationship  between  adenosine  and 
dopamine receptors (A2A/D2 and A1/D1) [66], a general in-
crease in extracellular adenosine could also decrease dopa-
minergic  transmission.  A  diverse  set  of  physiological  and 
pathological  stimuli  that  modulate  extracellular  adenosine 
are outlined in Table 1.  
Table 1.  Conditions that Increase Adenosine in the CNS 
Manipulation  Reference 
Hypoxia 
Fowler 1989 [55] 
Dale & Frenguelli 2000 [34] 
Saransaari & Oja 2003 [172] 
Martín, Fernández, Perea, Pascual, Haydon, 
Araque & Ceña 2007 [123] 
Ischemia 
Fowler 1990 [56] 
Latini, Corsi, Pedata & Pepeu 1995 [108] 
Frenguelli, Llaudet & Dale 2003 [63] 
Parkinson, Xiong & Zamzow 2005 [155] 
Frenguelli, Wigmore, Llaudet & Dale 2007 [64] 
NMDA receptor 
activation 
Manzoni, Manabe & Nicoll 1994 [119] 
Semba & White 1997 [176] 
Melani, Corsi, Giménez-Llort, Martínez, Ogren, 
Pedata & Ferré 1999 [130] 
Brambilla, Chapman & Greene 2005 [21] 
(Table 1. Contd….) 
Manipulation  Reference 
H2O2 
Masino, Mesches, Bickford & Dunwiddie  
1999 [129] 
Saransaari & Oja 2003 [172] 
Hypoglycemia or  
 impaired glycolysis 
Fowler 1993 [57] 
Zhu & Krnjević 1993 [201] 
Calabresi, Centonze, Pisani & Bernardi 1997 
[22] 
Zhao, Tekkök & Krnjević [200] 
Minor, Rowe, Soames Job, Ferguson [131] 
Increased tempera-
ture 
Gabriel, Klussman & Igelmund 1998 [67] 
Masino & Dunwiddie 1999 [124] 
Hypercap-
nia/acidification 
Dulla, Dobelis, Pearson, Frenguelli, Staley & 
Masino 2005 [42] 
Gourine, Llaudet, Dale & Spyer 2005 [77] 
Otsuguro, Yamaji, Ban, Ohta & Ito 2006 [146] 
Depolarization 
Pedata, Pazzagli, Tilli & Pepeu 1990 [157] 
Latini, Corsi, Pedata & Pepeu 1995 [108] 
Metabolic poisons 
Doolette1997 [40] 
Zhu & Krnjević 1997 [202] 
Saransaari & Oja 2003 [172] 
Astrocyte activation 
Zhang, Wang, Ye, Ge, Chen, Jiang, Wu, Poo & 
Duan 2003 [199] 
Parkinson & Xiong 2004 [154] 
Pascual, Casper, Kubera, Zhang, Revilla-




Whitcomb, Lupica, Rosen & Berman 1990 [193] 
During & Spencer 1993 [46] 
Berman, Fredholm, Aden & O’Connor 2000 
[11] 
Kaku, Jiang, Hada, Morimoto & Hayashi 2001 
[93] 
Etherington, Patterson, Meechan, Boison, 
Irving, Dale & Frenguelli 2008 [52] 
Intense exercise  Dworak, Diel, Voss, Hollman & Strüder 2007 
[47] 
Sleep deprivation 
Porkka-Heiskanen, Strecker, Thakkar, Bjorkum, 
Greene & McCarley 1997 [162]  
Porkka-Heiskanen, Strecker & McCarley  
2000 [161] 
Kalinchuk, McCarley, Stenberg, Porkka-
Heiskanen & Basheer 2008 [94] 
Murillo-Rodriguez, Liu, Blanco-Centurion & 
Shiromani, 2008 [133] 
An overview of both physiological and pathological conditions of altered metabolism 
and  cellular  activity  that  can  increase  extracellular  adenosine.  Due  to  the  rapid 
dephosphorylation  of  extracellular  ATP  to  adenosine,  increased  extracellular  ATP 
yields a net increase in adenosine. This table is not meant to be exhaustive of the litera-
ture, but to highlight the ubiquitous and rapid nature of the adenosine response and thus 
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ADENOSINE, METABOLISM AND EPILEPSY 
  The  inhibitory  adenosine  A1  receptor  is  functionally 
dominant in hippocampus and cerebral cortex, and underlies 
adenosine’s role as an endogenous anticonvulsant [43]. Ac-
cordingly,  any  manipulation  which  increases  extracellular 
adenosine offers significant potential for both preventing and 
halting epileptic seizures, the vast majority of which initiate 
and propagate in these forebrain regions. Unlike the point-to-
point and activity-dependent changes in synaptic  transmis-
sion effected by classical neurotransmitters, adenosine exerts 
a tonic modulatory influence on neuronal activity. Thus the 
anticonvulsant effects of adenosine are dissimilar mechanis-
tically to classical actions of glutamate and GABA, the neu-
rotransmitters targeted most often for the treatment of epi-
lepsy [168]. Adenosine itself is not packaged in vesicles, and 
its non-synaptic release, such as from astrocytes and through 
nucleoside  transporters,  can  influence  a  neural  “neighbor-
hood.” Akin to a broad-based influence of altered metabo-
lism, such as via ketogenic strategies, the presence of a tonic 
level of adenosine in the extracellular space makes adenosine 
a major player in the dynamics of nervous system activity 
and even in determining the set point of normal physiology 
versus pathology in brain function – such as by determining 
seizure  threshold.  Indeed,  local  release  of  adenosine  itself 
[89] or regulating local metabolism of adenosine by reducing 
its intracellular rephosphorylation by adenosine kinase [18] 
both  offer  significant  emerging  potential  for  treating  epi-
lepsy.  Importantly,  adenosine  is  effective  in  stopping  sei-
zures which  are pharmacoresistant [16], thus opening new 
therapeutic opportunities for intractable epilepsy. 
  Physiological conditions which offer both high ATP lev-
els  and  increased  extracellular  adenosine  are  particularly 
ideal for epilepsy and for many acute and chronic neurologi-
cal  disorders  characterized  by  metabolic  dysfunction  and 
neuronal vulnerability or frank progressive neurodegenera-
tion.  Enhanced  ATP  levels  provide  energy  reserves  for  a 
neuron  to  continue  functioning  under  stress,  essential  for 
maintaining cell calcium and other ion gradients across the 
cell  and  mitochondrial  membrane.  Increased  extracellular 
adenosine, at levels permitting normal synaptic transmission, 
plasticity  and  cognition,  offers  a  neuroprotective  buffer 
against insults, reduces excitation, and averts excessive ATP 
demand, expressly critical in cells with compromised energy 
capacity. Ideally, metabolic strategies enhance ATP, increase 
extracellular  adenosine,  and  boost  on-demand  adenosine 
within a neural neighborhood to provide local seizure control 
and neuroprotection. As such, metabolic and dietary strate-
gies such as ketogenic diet therapy may increase regional or 
global  adenosine  and  increase  overall  seizure  threshold  as 
described below. 
THE  REGULATION  OF  ADENOSINE  AND  BIO-
ENERGETICS BY KETOGENIC METABOLISM 
  Multiple lines of evidence suggest that adenosine, ATP, 
and  general  cellular  energy  are  upregulated  by  ketogenic 
metabolism. To highlight these effects, it is necessary to re-
view  the  underlying  biochemistry  of  ketosis.  Due  to  re-
stricted carbohydrate intake, blood glucose is very low dur-
ing chronic consumption of a ketogenic diet (or prolonged 
fasting). During conditions of limited glucose the liver main-
tains energy homeostasis by converting fatty acids and some 
amino acids to ketone bodies (β-hydroxybutyrate, acetoace-
tate,  acetone)  which  are  then  transported  by  the  blood  to 
other tissues for use as fuel. The brain is particularly depend-
ent on this process, since it is poor both at using fatty acids 
directly for fuel and at converting fatty acids to ketone bod-
ies;  the  brain  is  a  unique  tissue  in  this  regard  [65,  147]. 
While  the  enzymes  involved  in  ketone  body  synthesis  are 
detectable in brain, they are present at far lower levels than 
in liver [4, 27, 28].  
  Ketone bodies lead to energy production by conversion 
to  acetyl-CoA  which  then  enters  the  mitochondrial  tricar-
boxylic acid cycle, replacing pyruvate (derived from glyco-
lysis) as an acetyl-CoA source. The tricarboxylic acid cycle 
then leads as usual to proton flow out of the mitochondria 
matrix; this gradient in turn powers ATP production by ATP 
synthase in the mitochondrial inner membrane. Not only can 
ketone bodies substitute for glucose, metabolism of ketone 
bodies is more efficient than that of glucose, leading to more 
available energy for ATP synthesis. This effect derives from 
the higher heat of combustion of ketone bodies compared to 
pyruvate [187]; ketone body metabolism leads to reduction 
of the mitochondrial NAD couple (NAD
+/NADH) and oxi-
dation of the mitochondrial co-enzyme Q couple (Q/QH2). 
The difference between the redox potentials of these couples 
determines  the  magnitude  of  the  proton  gradient  which  in 
turn determines the free energy (ΔG’) of ATP hydrolysis – 
the increased difference with ketone body metabolism leads 
to increased ΔG’ for ATP production [187]. Key aspects of 
this energy cycle and its relationship to adenosine are sum-
marized in Fig. (1). 
  Experimental application of ketone bodies in vitro leads 
to increased ATP/ADP  and phosphocreatine/creatine ratios 
and increased levels of the tricarboxylic acid cycle substrates 
citrate and isocitrate [95, 173]. Overall, studies of ketogenic 
metabolism in the brain demonstrate an increased energetic 
status using measures ranging from respiration to mitochon-
drial density to levels of energy-storing substances such as 
ATP and phosphocreatine. Importantly, the brain’s bioener-
getic response to ketosis  appears  to differ from peripheral 
tissues so far examined – increases in cell energy predomi-
nate in brain (Table 2). 
  In addition to published neurochemical and biochemical 
evidence, recent neurochemical evidence suggests a regional 
upregulation of energy molecules in rats after maintenance 
on  a  ketogenic  diet.  Preliminary  results  demonstrate  in-
creased  ATP  or  adenosine  in  specific  brain  regions  [127, 
143], including a significant increase in ATP and a strong 
trend toward increased  adenosine  in cerebral  cortex [127], 
and  upregulated  ATP  synthase  gene  expression  in  hippo-
campus [20, 141]. Field recordings from the CA1 region of 
hippocampal slices show a reduced electrophysiological re-
sponse to hypoxia [20] and exogenous adenosine [127] after 
ketogenic diet therapy, consistent with increased endogenous 
adenosine. Hippocampal CA3 pyramidal neurons autoregu-
late  their  activity  based  on  acute  changes  in  intracellular 
ATP and extracellular glucose consistent with the metabolic 
consequences of ketogenic diet therapy [96]; detailed cellular 
mechanisms are described below.  260    Current Neuropharmacology, 2009, Vol. 7, No. 3  Masino et al. 
  As  noted  above,  ketogenic  metabolism  occurs  during 
restricted  glucose  and  is  characterized  by  increased  ATP. 
During single-cell patch clamp recordings, when extracellu-
lar glucose is reduced but not eliminated, and the level of 
intracellular ATP is sufficient or high in the patch pipette, 
CA3  pyramidal  neurons  regulate  their  own  excitability  by 
releasing ATP, activating adenosine A1 receptors and open-
ing postsynaptic K
+ channels [96]. In contrast, during single 
cell recordings of CA3 pyramidal neurons, when extracellu-
lar  glucose  is  reduced  and  intracellular  ATP  is  low,  CA3 
pyramidal  cells  depolarize  significantly  [96].  These  low 
ATP/low glucose conditions are similar to an ischemic stroke, 
where both oxidative phosphorylation and glucose availabil-
ity  are  interrupted.  Thus,  an  autocrine  regulation  of  CA3 
neuron excitability during low glucose depends critically on 
intracellular  ATP;  the  subsequently  increased  extracellular 
adenosine likely influences nearby neurons, particularly im-
portant in CA3, a region with recurring excitatory collaterals. 
Overall this concurrent intracellular ATP / extracellular glu-
cose manipulation mimicking metabolic aspects of ketogenic 
diet therapy provides a clear example of a situation where 
intracellular  ATP  is  high  yet  extracellular  adenosine  in-
creases – ideal for autocrine regulation by increasing seizure 
threshold and promoting neuronal survival.  
  Evidence for autocrine neuronal regulation is consistent 
with adenosine’s role as a neuroprotective agent, mobilized 
proactively  under  these  conditions  by  non-pathological 
changes in altered metabolism. Similarly, ketone-based me-
tabolism  [35]  or  a  ketogenic  diet  [70]  has  already  shown 
neuroprotective properties in injury models in multiple brain 
regions.  While  it  seems  counterintuitive  for  brain  cells  to 
release  ATP  when  extracellular  glucose  is  low,  ultimately 
this process can save cell energy: under conditions of suffi-
cient ATP, there is a large ratio of ATP:adenosine (10,000:1) 
inside the cell. Upon releasing a relatively small amount of 
ATP,  a  coherent  set  of  mechanisms  degrade  extracellular 
ATP to adenosine, activate adenosine A1 receptors and re-
duce excitability. Thus, releasing a relatively small amount 
of ATP during low glucose is a powerful preemptive strike 
against  a  condition  of  increased  excitability  –  potentially 
placing energy demands which could exceed energy supply 
and compromise neuronal function.  
CLINICAL IMPLICATIONS 
  The  clinical  efficacy  of  a  ketogenic  diet  is  well-estab-
lished for pediatric epilepsy. It has been validated retrospec-
tively by multiple clinical sites [38, 62, 153, 188] and con-
firmed recently in a randomized controlled trial [135]. Simi-
lar to adenosine, the ketogenic diet is effective in medically-
refractory  epilepsy,  and  thus  reduces  seizures  via  mecha-
nisms other than those targeted by antiepileptic drugs avail-
able  currently  [168].  A  significant  subset  of  pediatric  epi-
lepsy patients become and remain seizure-free, and can re-
duce or eliminate their medication even after discontinuing 
diet therapy. Most common side effects are short term, and 











Fig. (1). The metabolic relationship between ketones and adenosine. Compounds upregulated by a ketogenic diet or exogenous ketones are 
italicized. (1) During ketolytic metabolism, the ketone bodies β-hydroxybutyrate (and its breakdown products acetone and acetoacetate) are 
either generated locally or hepatically and transported via the blood to other tissues (such as brain). Ketones are converted intracellularly into 
acetyl-CoA which enters the tricarboxylic acid cycle. (2) This mitochondrial energy cycle generates, at multiple steps (----), protons and elec-
trons that are channeled to the electron transport chain by NADH and FADH2 (β-hydroxybutyrate conversion to acetoacetate also contrib-
utes). Many steps of the tricarboxylic acid cycle are omitted for simplicity. (3) The electron transport chain drives an electrochemical gradi-
ent across the mitochondrial outer membrane and ultimately oxidative phosphorylation which forms ATP from ADP and phosphate (Pi) by 
ATP synthase. (4) Enhanced ATP can be converted to phosphocreatine for energy storage, or broken down to its core molecule, adenosine. 
Adenosine levels inside and outside of the cell membrane are influenced concurrently by an equilibrative transporter. Due to the very large 
ATP / adenosine ratio inside the cell, a small increase in intracellular ATP could translate into a large relative increase in intracellular, and 
thus extracellular, adenosine. Adenosine, Ketogenic Diet and Epilepsy  Current Neuropharmacology, 2009, Vol. 7, No. 3    261 
ever, kidney stones can develop in 5-7% of children on the 
diet [171].  
  The ketogenic diet may also offer benefits for adult epi-
lepsy [15], and recently has been shown to improve dramati-
cally or even reverse the metabolic syndrome which charac-
terizes type II diabetes [198]. Notably, a ketogenic diet was 
more effective than a calorically restricted diet, and virtually 
reversed metabolic syndrome in all persons who were able to 
comply with the restrictions of dietary therapy [192]. Basic 
research has also shown dramatic results in slowing tumor 
growth in brain cancer [177], and synergistic effects of the 
simultaneous  use  of  a  ketogenic  diet  and  2-deoxyglucose 
[121],  a  metabolic  manipulation  which  inhibits  glycolysis, 
increases adenosine [200] and decrease seizures [69, 181]. 
Thus,  the  therapeutic  applications  of  a  ketogenic  diet  and 
metabolism-based  therapies  are broadening rapidly beyond 
pediatric epilepsy to other chronic and prevalent conditions.  
  As a whole, the capacity for a ketogenic diet to increase 
specifically  the  influence  of  endogenous  adenosine  offers 
testable  and  clinically-relevant  predictions;  many  of  these 
predictions are validated by published clinical and basic re-
search, lending further conceptual support [125, 126]. Below 
we highlight briefly some of the central nervous system im-
plications  of  a  relationship  between  a  ketogenic  diet  and 
adenosine. A subset is supported strongly by published re-
search,  in  particular  neuroprotection  and  sleep.  Data  are 
emerging  for  neurodegeneration,  hyperdopaminergic  disor-
ders and autism. In addition, we speculate upon major clini-
cal implications for pain.  
Brain Injury 
  The  attractive  features  of  adenosine  as  an  endogenous 
anticonvulsant are recapitulated in its role as a neuroprotec-
tive  molecule.  Increasing  adenosine’s  inhibitory  influence 
via the adenosine A1 receptor protects neurons in virtually 
any model of brain injury [45], and the adenosine A1 recep-
tor has long been a major focus of and goal for adenosine-
based neuroprotective therapies. Increasing the influence of 
adenosine at A1 receptors offers neuroprotection either be-
fore [90] or after [190] the injury. Unfortunately, and akin to 
epilepsy, the peripheral side effects of receptor-based strate-
gies have stymied drug development and adenosine A1 re-
ceptors have lost  momentum  as  a primary neuroprotective 
target.  
  Importantly,  and  as  predicted  based  on  a  relationship 
between  ketone  metabolism  and  adenosine,  the  ketogenic 
diet or analogous metabolic strategies have shown neuropro-
tective properties in multiple brain injury models and brain 
regions,  including spinal  cord injury [160]. Some of these 
effects  have  been  counterintuitive  –  neuroprotection  was 
observed after a ketogenic strategy such as fasting [35], or 
after strategies that interrupted metabolism [102] or inhibited 
glycolysis [111]. Importantly, neuroprotection was observed 
even  if  altered  metabolism  was  initiated  after  the  injury 
[152], making this a particularly promising strategy. Based 
on  differential  consequences  and  responses  in  the  central 
nervous system versus the periphery (Table 2), a metabolic 
strategy could lend new therapies and recommendations for 
the treatment of brain injuries, and open a new and exciting 
chapter for adenosine and neuroprotection. 
Neurodegeneration  
  The neuroprotective effects of adenosine via altered me-
tabolism  may  extend  to  neurodegenerative  diseases.  Meta-
bolic dysregulation at the cellular level is a hallmark of many 
chronic and neurodegenerative disorders [7], and often it is 
unclear if it causes and/or results from the progressive neu-
ronal dysfunction. The brain has an extremely high fat con-
tent,  and  as  noted  in  Table 2   offers  some  differential  re-
sponses to metabolic manipulations as compared to periph-
eral tissues. These dual and unique features of brain compo-
sition and brain metabolism enhance therapeutic opportuni-
ties for chronic  and progressive disorders [1], and suggest 
the potential for limited or reduced peripheral side effects.  
  As one  example, metabolic therapy may offer  sympto-
matic delay or improvement even in a genetic, neurodegen-
erative disorder such as Huntington’s disease [41, 186]. Drug 
treatments targeting type II diabetes, which, similar to a ke-
Table 2.  Influence of Ketone Metabolism on Cellular Energy 
  Energetic Molecules 
Expression of Mitochondrial  
Genes or Proteins 
Mitochondria  Respiration 
Brain 
Increased ATP [37, 99, 127, 
134, 143] 
Increased phosphocreatine [20, 
151] 
Upregulated ATP synthase [20, 141] 
Upregulated uncoupling protein 
[182] 
Unchanged succinate dehydrogenase 
[167] 
Increased number [20, 143] 
Increased or reduced number 
(region-dependent) [6] 
Increased respiration [182] 
Peripheral tis-
sues 
Unchanged ATP production 
[158] 
Unchanged citrate synthase [158] 
Unchanged succinate dehydrogenase 
[137, 167] 
Moderately increased size [48] 
Unchanged [6] 
 
Evidence for changes in cellular energy in brain and peripheral tissues after ketogenic metabolism in vivo or in vitro. An increase or upregulation is indicated by italics throughout. 
“Expression of genes or proteins” includes mRNA expression and protein expression via immunochemical or activity-based assays; here we include both cell and mitochondria-
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togenic  diet,  offer  improved  glycemic  control,  can  reduce 
symptoms  and  increase  survival  in  mouse  models  of 
Huntington’s disease [116, 122]. With gene therapy still be-
yond  the  near-term  horizon,  metabolic  treatment  strategies 
which delay or reduce symptoms of disease could offer sig-
nificant improvements in quality of life for current patients 
with Huntington’s disease and a host of neurodegenerative 
conditions. In addition, at least some neurodegenerative dis-
eases are associated with an increased risk of seizures, such 
as Alzheimer’s disease [3]. It is unknown whether subclini-
cal seizures may occur and contribute to the progression of 
Alzheimer’s  disease  or  other  neurodegenerative  diseases  
in humans. Ultimately, similar to epilepsy, adenosine-based 
metabolic therapies could limit acute dysfunction and offer 
ongoing  neuroprotection  against  progressive  neuronal  de-
cline and degeneration. 
Sleep 
  Adenosine promotes sleep [165, 189], and treating sleep 
disorders and enhancing the quality of sleep is a major con-
cern  for  public  health  [23].  The  specific  adenosine-based 
mechanism established initially as sleep-promoting was in-
creased  activity  at  the  A1  receptor  in  the  basal  forebrain 
[166]. More recently  the adenosine A2A receptor has been 
recognized  for  an  important  role  in  sleep  [88,  174].  The 
alerting  effects  of  caffeine  are  attributed  to  its  actions  at 
adenosine receptors in forebrain areas important for cogni-
tion as well as arousal centers, and it may be that endoge-
nous  adenosine  acting  at  both  of  the  receptor  subtypes  in 
brain that are antagonized by caffeine – A1 and A2A adeno-
sine receptors – play a role in sleep behaviors [8].  
  In keeping with adenosine’s role as a sleep-promoter, and 
the potential for a ketogenic diet to increase ATP and ex-
tracellular adenosine, the ketogenic diet has been shown to 
improve sleep quality and quantity in children with epilepsy, 
especially normalizing the ultradian cycling between slow-
wave  and  paradoxical  sleep  [83].  Sleep  electroencephalo-
graph (EEG) changes were observed consistently with keto-
genic  diet  therapy,  and  normalization  or  improvement  in 
sleep EEG was correlated with an improvement in seizures 
[153].  In  control  subjects  without  a  diagnosis  of  epilepsy, 
effects are typically moderate and include reports of an in-
crease  in the latency  to enter rapid eye movement (REM) 
sleep [106] and an increase in slow-wave sleep [2]. Whereas 
a high-fat, low-carbohydrate ketogenic diet increased slow-
wave sleep, a high-carbohydrate, low-fat isocaloric diet de-
creased slow-wave sleep [159].  
  Recent evidence implicates the role of extracellular as-
trocyte-derived ATP as critical for the sleep-promoting in-
fluence of adenosine [82]. Furthermore, there is a well estab-
lished  association  between  poor  sleep  and  epilepsy  [105]. 
With such a high prevalence and cost associated with these 
co-morbidities, metabolic therapy appears to offer significant 
promise. More research is needed in this area to determine 
the  therapeutic  relationship  among  adenosine,  a  ketogenic 
diet and sleep.  
Autism 
  Multiple lines of evidence suggest that the influence of 
adenosine may be insufficient in autism spectrum disorders 
(ASD),  and  that  increasing  adenosine  would  reduce  both 
physiological and behavioral hallmarks of ASD. Preliminary 
studies have shown that the ketogenic diet improves symp-
toms of autism [53], and Rett syndrome [80]. To our knowl-
edge, dysregulation of adenosine in brain has not been tested 
directly with respect to symptoms of autism, although these 
studies  are  underway.  Nevertheless,  adenosine  is  a  purine 
molecule with roles in both metabolism and neuronal signal-
ing,  and  abnormalities  in  purine  metabolism  have  been 
documented [19, 120, 142, 149, 150] in a subset of ASD. 
  Along with dysregulation of purine metabolism, ASD are 
characterized by several behavioral and physiological hall-
marks  of  disordered  adenosine:  sleep  disruption  [25,  72, 
184], markedly increased incidence of seizures [118, 195], 
immune dysfunction [87, 91], and reports - including self-
reports - of increased anxiety and “sensitivity” and “hyperac-
tivity” of the nervous system [24, 78, 178]. Often there is a 
dual  diagnosis,  with  psychiatric  comorbidities  present  in 
least  70%  of  individuals  diagnosed  with  ASD.  The  most 
common comorbidities are social anxiety disorder, attention-
deficit/hyperactivity disorder, and oppositional defiant disor-
der [178].  
  Many of the behaviors exhibited by persons with autism 
and/or  reported  by  high-functioning  persons  with  autism 
involve  stimuli  that  would  be  predicted  to  release  ATP 
and/or adenosine based on associated mechanical pressure, 
increased neuronal activity, decreased pH or increased tem-
perature (ref. [45] and Table 1). For example, rocking, spin-
ning and Grandin’s well-known “Hug Machine” [49] all ex-
ert mechanical pressure or sudden changes in acceleration, 
intense  intellectual  activity  and  focus  can  reduce  anxiety 
associated with ASD [78], and intense neuronal activity in-
creases extracellular adenosine [114]. Intense exercise causes 
a  metabolic  decrease  in  pH  [84],  decreased  pH  has  been 
shown to increase adenosine [42, 146], and intense exercise 
has  been  shown  to  increase  brain  adenosine  [47]  and  im-
prove  symptoms  of  autism  [98].  Reports  show  improved 
behavior,  language  and  social  function  associated  with  a 
fever in persons with autism [30], and basic research demon-
strates  that  a  similar  temperature  increase  in  hippocampal 
slices increases extracellular adenosine and inhibits neuronal 
activity significantly [124]. 
  Certainly many symptoms and behaviors of ASD are due 
to  aberrant  neurochemistry,  neuroanatomical  development 
and genetically-determined substrates. However, increasing 
the inhibitory influence of adenosine could help significantly 
with multiple behavioral and physiological sequelae. Impor-
tantly, increasing  adenosine  improves sleep, decreases sei-
zures  and  reduces  anxiety  –  all  physiological  effects  that 
could be achieved by a metabolic strategy such as a keto-
genic diet and would improve quality of life significantly in 
persons and families affected by ASD. Ketogenic diet ther-
apy  and/or  increasing  adenosine  could  improve  social  and 
behavioral symptoms and reduce or alleviate serious chronic 
physiological  symptoms  which  impact  the  ability  to  learn 
and  remember  (sleep  disruption/inadequate  REM  sleep/ 
seizures  [86,  118])  and  ultimately  cause  permanent  brain 
dysfunction  and  cognitive  impairment  (recurrent  seizures) 
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activity, sleep and seizures, the relationship among metabo-
lism, autism and adenosine, including the efficacy of a keto-
genic diet in reducing symptoms of autism, needs to be ex-
plored directly. 
Hyperdopaminergic Disorders 
  Dopamine  and  adenosine  have  long  been  known  to be 
opposing at numerous levels. Behaviorally, whereas adeno-
sine receptor antagonists (e.g. caffeine) are stimulants, such 
properties belong to agonists of the dopamine system (e.g. 
amphetamine). Biochemically, the two high affinity adeno-
sine receptors in brain each have an antagonistic dopaminer-
gic counterpart. Specifically, A1 and D1 receptors, and A2A 
and  D2  receptors,  have  opposing  effects  on  2
nd  messenger 
pathways,  most  notably  the  production  of  cyclic  AMP 
through  heterotrimeric  G-protein  regulation  of  adenylate 
cyclase [61, 97]. More recently, it has become apparent that 
such interactions can involve direct receptor/receptor cross-
talk via A1/D1 and A2A/D2 receptor heteromers [54]. There-
fore, it is logical to explore modulation of adenosinergic ac-
tivity as a possible treatment for disorders of dopaminergic 
function.  
  Thus far there is compelling evidence that adenosine an-
tagonists are useful in treating a hypodopaminergic disease, 
namely Parkinson’s disease [197]. Conversely, the ketogenic 
diet and an associated augmentation of adenosine may be of 
use in hyperdopaminergic states. The list of clinical condi-
tions that are hypothesized to involve overactivity in the do-
pamine system is impressive, and includes conditions as di-
verse  as  schizophrenia,  tardive  dyskinesia,  attention  defi-
cit/hyperactivity disorder, Tourette’s syndrome, Huntington’s 
disease,  and  drug  addiction/relapse.  Research  in  animal 
models  of  some  of  these  disorders  suggests  the  beneficial 
effects of promoting adenosine [12, 14, 39, 71, 92, 101, 113, 
191]. Adenosine augmentation via ketogenic diet or analo-
gous metabolic strategies may be particularly useful in those 
hyperdopaminergic  disorders  involving  neurodegeneration, 
offering the combined benefits of treating symptoms as well 
as retarding the underlying degeneration.  
  Preliminary human data exist on the benefits of ketogenic 
diet therapy and schizophrenia [148]. Ketogenic diet therapy 
was  tried  because  the  physiological  effects  of  other  treat-
ments  –  such  as  electroconvulsive  shock  –  result  in  de-
creased  blood  pH,  and  ketone  metabolism  increases  acid 
production. In addition, physicians noted carbohydrate crav-
ings and increased intake prior to a relapse and hypothesized 
that  persons  with  schizophrenia  may  have  problematic  or 
altered carbohydrate metabolism. Despite the small sample 
size and incomplete control over dietary therapy, promising 
results were noted [148].  
  Like epilepsy, schizophrenia is a chronic condition char-
acterized by recurring episodes as well as significant propor-
tion  of  cases  that  remain  intractable  to  therapies  available 
currently [107]. Finally, given the high coincident rates of 
epilepsy  and schizophrenia [164] and type II diabetes and 
schizophrenia [39, 139, 144, 179], and the success of a vari-
ety of low carbohydrate and ketogenic diets in treating type 
II  diabetes  [198]  and  adult  epilepsy  [5,  103,  104],  dietary 
therapy  would  seem  like  an  optimal  primary  or  adjuvant 
therapy to reduce all of these medical conditions. 
Pain  
  Control of chronic pain remains a major clinical problem. 
For example, the strongest analgesics, the opiates, have been 
viewed  historically  as  poorly  effective  against  neuropathic 
pain; only a subset of patients respond well to opiates [163]. 
Anticonvulsant drugs are a non non-opiate alternative used 
with  success  against  neuropathic  pain,  yet  they  have  their 
own set of undesirable side effects. Pain relief using anticon-
vulsants demonstrates that an overall inhibition of neuronal 
activity is a strategy that can alleviate pain, and so it is not 
surprising that adenosine persists as a prized, but problem-
atic, target for pain relief [180]. Adenosine A1 receptor ago-
nists given systemically reduce chronic pain  effectively in 
experimental  animals  [31,  112],  and  conversely,  genetic 
knockout of the A1 receptor enhances pain sensitivity [90, 
196].  Clinically,  systemic  adenosine  alleviates  neuropathic 
pain [10], yet the presence of adenosine A1 receptors in the 
heart  and other peripheral tissues,  and the short biological 
half-life of adenosine in the blood, have stymied this type of 
therapy. Side effects can be avoided with intrathecal adeno-
sine [9, 50], but this route of administration is obviously in-
vasive.  
  Based  on  evidence  that  ketogenic  strategies  increase 
adenosine in the  central nervous system, they will also be 
likely to alleviate pain, although research on this topic has 
only begun [203]. The parallels between ketogenic diets and 
adenosine  A1  receptor  activation  include  their  efficacy  in 
pharmocoresistant epilepsy, and neuronal inhibition via anti-
convulsants appears to be one mechanism for alleviating at 
least a subset of neuropathic pain. We suggest that adeno-
sine-mediated  central  nervous  system  inhibition  via  meta-
bolic strategies such as ketogenic diet therapy will be effec-
tive against neuropathic pain.  
  Beyond these possible effects on the neural substrates of 
pain generally, a ketogenic metabolism may have beneficial 
effects  with  inflammatory  pain  by  reducing  inflammation 
itself through several mechanisms. 1) adenosine A1 receptors 
have  been  shown  to  be  anti-inflammatory  in  a  number  of 
tissues, including brain [68, 110, 183, 185]. 2) Compared to 
glycolytic metabolism, ketolytic metabolism produces fewer 
reactive oxygen species, which are known to contribute to 
inflammation [81, 117, 187]; 3) the long-chain polyunsatu-
rated fatty  acids  in  the ketogenic diet activate peroxisome 
proliferator-activated receptors, an effect which will reduce 
inflammation by inhibiting nuclear factor κB and other pro-
inflammatory pathways [13, 32, 33, 115]. Altogether, multi-
ple consequences of ketone metabolism, including increased 
adenosine,  appear  to  have  much  clinical  promise  as  safe, 
effective,  non-addictive  treatments  for  chronic  neuropathic 
and inflammatory pain conditions.  
SUMMARY 
  Herein we highlight major implications of the emerging 
relationship among adenosine, a ketogenic diet and epilepsy 
and provide a broad and provocative overview of a subset of 
the  therapeutic  predictions  of  this  metabolic  relationship. 
The clinical implications discussed in detail are supported by 
preliminary or historical data, or by infrequent publication in 
disparate fields of research, and deserve further examination 
and integration. An evidence–based metabolic treatment as 264    Current Neuropharmacology, 2009, Vol. 7, No. 3  Masino et al. 
an adjuvant or alternate strategy is particularly attractive and 
important as we seek cost-effective solutions for the diverse 
conditions  highlighted  herein.  Together  these  conditions 
exact an enormous toll on health care and quality of life as 
they are chronic, prevalent, increasing (particularly diabetes 
and autism), and often  comorbid (sleep disorders and  epi-
lepsy, for example).  
  In the central nervous system, adenosine offers unparal-
leled yet untapped opportunities for seizure protection, neu-
roprotection,  sleep,  and  pain  relief,  among  others.  Under-
standing  the  regulation  of  adenosine  helps  achieve  these 
long-standing clinical goals and extends beyond them to al-
leviating  both  acute  and  chronic  conditions  in  adults  and 
children.  In  summary,  the  metabolic  relationship  among 
adenosine, a ketogenic diet, and epilepsy could open major 
new  therapeutic  applications  and  avoid  peripheral  side  ef-
fects in a way that has eluded receptor-based strategies.  
ACKNOWLEDGEMENTS  
  We acknowledge the support of NIH (NINDS), the Na-
tional Science Foundation and Trinity College. 
REFERENCES 
[1]  Adibhatla, R.M., Hatcher, J.F. (2008) Altered lipid metabolism in 
brain injury and disorders. Subcell. Biochem., 49, 241-268. 
[2]  Afaghi, A., O'Connor, H., Chow, C.M. (2008) Acute effects of the 
very low carbohydrate diet on sleep indices. Nutr. Neurosci., 11, 
146-154. 
[3]  Amatniek, J.C., Hauser, W.A., DelCastillo-Castaneda, C., Jacobs, 
D.M., Marder, K., Bell, K., Albert, M., Brandt, J., Stern, Y. (2006) 
Incidence and predictors of seizures in patients with Alzheimer's 
disease. Epilepsia, 47, 867-872. 
[4]  Auestad, N., Korsak, R.A., Morrow, J.W., Edmond, J. (1991) Fatty 
acid oxidation and ketogenesis by astrocytes in primary culture. J. 
Neurochem., 56, 1376-1386. 
[5]  Baborka,  C.J.  (1930)  Epilepsy  in  adults:  results  of  treatment  by 
ketogenic diet in one hundred cases. Arch. Neurol., 6, 904-914. 
[6]  Balietti, M., Giorgetti, B., Fattoretti, P., Grossi, Y., Di Stefano, G., 
Casoli, T., Platano, D., Solazzi, M., Orlando, F., Aicardi, G., Ber-
toni-Freddari, C. (2008) Ketogenic diets cause opposing changes in 
synaptic  morphology  in  CA1  hippocampus  and  dentate  gyrus  of  
late-adult rats. Rejuvenation Res., 11, 631-640. 
[7]  Barañano, K.W., Hartman, A.L. (2008) The ketogenic diet: uses in 
epilepsy  and  other  neurologic  illnesses.  Curr.  Treat.  Options  
Neurol., 10, 410-419. 
[8]  Basheer,  R.,  Strecker,  R.E.,  Thakkar,  M.M.,  McCarley,  R.W. 
(2004) Adenosine and sleep-wake regulation. Prog. Neurobiol., 73, 
379-396. 
[9]  Belfrage,  M.,  Segerdahl,  M.,  Arnér,  S.,  Sollevi,  A.  (1999)  The 
safety and efficacy of intrathecal adenosine in patients with chronic 
neuropathic pain. Anesth. Analg., 89, 136-142. 
[10]  Belfrage, M., Sollevi, A., Segerdahl, M., Sjölund, K.F., Hansson, P. 
(1995)  Systemic  adenosine  infusion  alleviates  spontaneous  and 
stimulus evoked pain in patients with peripheral neuropathic pain. 
Anesth. Analg., 81, 713-717. 
[11]  Berman, R.F., Fredholm, B.B., Aden, U., O'Connor, W.T. (2000) 
Evidence for increased dorsal hippocampal adenosine release and 
metabolism  during  pharmacologically  induced  seizures  in  rats. 
Brain Res., 872, 44-53. 
[12]  Bishnoi, M., Chopra, K., Kulkarni, S.K. (2007) Protective effect of 
adenosine reuptake inhibitors in haloperidol-induced orofacial dy-
skinesia and associated behavioural, biochemical and neurochemi-
cal changes. Pharmacology, 79, 171-183. 
[13]  Blanquart, C.,  Barbier, O.,  Fruchart, J.C.,  Staels, B., Glineur,  C. 
(2003)  Peroxisome  proliferator-activated  receptors:  regulation  of 
transcriptional activities and roles in inflammation. J. Steroid Bio-
chem. Mol. Biol., 85, 267-273. 
[14]  Blum, D., Gall, D., Galas, M.C., d'Alcantara, P., Bantubungi, K., 
Schiffmann, S.N. (2002) The adenosine A1 receptor agonist adeno-
sine amine congener exerts a neuroprotective effect against the de-
velopment  of  striatal  lesions  and  motor  impairments  in  the  3-
nitropropionic acid model of neurotoxicity. J. Neurosci., 22, 9122-
9133. 
[15]  Bodenant,  M.,  Moreau,  C.,  Sejourné,  C.,  Auvin,  S.,  Delval,  A., 
Cuisset, J.M., Derambure, P., Destée, A., Defebvre, L. (2008) In-
terest  of  the  ketogenic  diet  in  a  refractory  status  epilepticus  in 
adults. Rev. Neurol. (Paris), 164, 194-199. 
[16]  Boison,  D.  (2007)  Adenosine-based  cell  therapy  approaches  for 
pharmacoresistant epilepsies. Neurodegener. Dis., 4, 28-33. 
[17]  Boison, D. (2008) Adenosine as a neuromodulator in neurological 
diseases. Curr. Opin. Pharmacol., 8, 2-7. 
[18]  Boison,  D.  (2008)  The  adenosine  kinase  hypothesis  of  epilepto-
genesis. Prog. Neurobiol., 84, 249-262. 
[19]  Bottini, N., De Luca, D., Saccucci, P., Fiumara, A., Elia, M., Por-
firio, M.C., Lucarelli, P., Curatolo, P. (2001) Autism: evidence of 
association with adenosine deaminase genetic polymorphism. Neu-
rogenetics, 3, 111-113. 
[20]  Bough,  K.J.,  Wetherington,  J.,  Hassel,  B.,  Pare,  J.F.,  Gawryluk, 
J.W., Greene, J.G., Shaw, R., Smith, Y., Geiger, J.D., Dingledine, 
R.J. (2006) Mitochondrial biogenesis in the anticonvulsant mecha-
nism of the ketogenic diet. Ann. Neurol., 60, 223-235. 
[21]  Brambilla, D., Chapman, D., Greene, R. (2005) Adenosine media-
tion of presynaptic feedback inhibition of glutamate release. Neu-
ron, 46, 275-283. 
[22]  Calabresi,  P.,  Centonze,  D.,  Pisani,  A.,  Bernardi,  G.  (1997)  En-
dogenous adenosine mediates the presynaptic inhibition induced by 
aglycemia at corticostriatal synapses. J. Neurosci., 17, 4509-4516. 
[23]  Caruso, C.C. (2006) Possible broad impacts of long work hours. 
Ind. Health, 44, 531-536. 
[24]  Chalfant,  A.M.,  Rapee,  R.,  Carroll,  L.  (2007)  Treating  anxiety 
disorders in children with high functioning autism spectrum disor-
ders: a controlled trial. J. Autism Dev. Disord., 37, 1842-1857. 
[25]  Chen, F., Lemonnier, E., Lazartigues, A., Planche, P. (2006) Sleep 
problems and information processing, a "disconnection effect" in 
autism? Med. Hypotheses, 66, 1245-1246. 
[26]  Chez, M.G., Chang, M., Krasne, V., Coughlan, C., Kominsky, M., 
Schwartz, A. (2006) Frequency of epileptiform EEG abnormalities 
in a sequential screening of autistic patients with no known clinical 
epilepsy from 1996 to 2005. Epilepsy Behav., 8, 267-271. 
[27]  Cullingford, T.E., Dolphin, C.T., Sato, H. (2002) The peroxisome 
proliferator-activated  receptor  α-selective  activator  ciprofibrate 
upregulates expression of genes encoding fatty acid oxidation and 
ketogenesis  enzymes  in  rat  brain.  Neuropharmacology,  42,  724-
730. 
[28]  Cullingford, T.E., Eagles, D.A., Sato, H. (2002) The ketogenic diet 
upregulates expression of the gene encoding the key ketogenic en-
zyme  mitochondrial  3-hydroxy-3-methylglutaryl-CoA  synthase  in 
rat brain. Epilepsy Res., 49, 99-107. 
[29]  Cunha, R.A. (2001) Adenosine as a neuromodulator and as a ho-
meostatic regulator in the nervous system: different roles, different 
sources and different receptors. Neurochem. Int., 38, 107-125. 
[30]  Curran,  L.K.,  Newschaffer,  C.J.,  Lee,  L.C.,  Crawford,  S.O., 
Johnston,  M.V.,  Zimmerman,  A.W.  (2007)  Behaviors  associated 
with fever in children with autism spectrum disorders. Pediatrics, 
120, e1386-e1392. 
[31]  Curros-Criado,  M.M.,  Herrero,  J.F.  (2005)  The  antinociceptive 
effects of the systemic adenosine A1 receptor agonist CPA in the 
absence and in the presence of spinal cord sensitization. Pharma-
col. Biochem. Behav., 82, 721-726. 
[32]  Cuzzocrea, S., Mazzon, E., Dugo, L., Patel, N.S., Serraino, I., Di 
Paolo,  R.,  Genovese,  T.,  Britti,  D.,  De  Maio,  M.,  Caputi,  A.P., 
Thiemermann, C. (2003) Reduction in the evolution of murine type 
II  collagen-induced  arthritis  by  treatment  with  rosiglitazone,  a 
ligand  of  the  peroxisome  proliferator-activated  receptor  gamma. 
Arthritis Rheum., 48, 3544-3556. 
[33]  Cuzzocrea, S., Pisano, B., Dugo, L., Ianaro, A., Maffia, P., Patel, 
N.S.,  Di  Paola,  R.,  Ialenti,  A.,  Genovese,  T.,  Chatterjee,  P.K.,  
Di Rosa, M., Caputi, A.P., Thiemermann, C. (2004) Rosiglitazone, 
a ligand of the peroxisome proliferator-activated receptor-gamma, 
reduces acute inflammation. Eur. J. Pharmacol., 483, 79-93. 
[34]  Dale, N., Pearson, T., Frenguelli, B.G. (2000) Direct measurement 
of adenosine release during hypoxia in the CA1 region of the rat 
hippocampal slice. J. Physiol., 526, 143-155. Adenosine, Ketogenic Diet and Epilepsy  Current Neuropharmacology, 2009, Vol. 7, No. 3    265 
[35]  Davis,  L.M.,  Pauly,  J.R.,  Readnower,  R.D.,  Rho,  J.M.,  Sullivan, 
P.G. (2008) Fasting is neuroprotective following traumatic brain in-
jury. J. Neurosci. Res., 86, 1812-1822. 
[36]  de Mendonça, A., Almeida, T., Bashir, Z.I., Ribeiro, J.A. (1997) 
Endogenous adenosine attenuates long-term depression and depo-
tentiation in the CA1 region of the rat hippocampus. Neurophar-
macology, 36, 161-167. 
[37]  DeVivo, D.C., Leckie, M.P., Ferrendelli, J.S., McDougal, D.B., Jr. 
(1978) Chronic ketosis and cerebral metabolism. Ann. Neurol., 3, 
331-337. 
[38]  DiMario, F.J., Jr., Holland, J. (2002) The ketogenic diet: a review 
of the experience at Connecticut Children's Medical Center. Pedi-
atr. Neurol., 26, 288-292. 
[39]  Dionyssopoulos,  T.,  Hope,  W.,  Coupar,  I.M.  (1992)  Effect  of 
adenosine analogues on the expression of opiate withdrawal in rats. 
Pharmacol. Biochem. Behav., 42, 201-206. 
[40]  Doolette, D.J. (1997) Mechanism of adenosine accumulation in the 
hippocampal slice during energy deprivation. Neurochem. Int., 30, 
211-223. 
[41]  Duan, W., Guo, Z., Jiang, H., Ware, M., Li, X.J., Mattson, M.P. 
(2003)  Dietary  restriction  normalizes  glucose  metabolism  and 
BDNF levels, slows disease progression, and increases survival in 
huntingtin  mutant  mice.  Proc.  Natl.  Acad.  Sci.  USA,  100,  2911-
2916. 
[42]  Dulla, C.G., Dobelis, P., Pearson, T., Frenguelli, B.G., Staley, K.J., 
Masino, S.A. (2005) Adenosine and ATP link PCO2 to cortical ex-
citability via pH. Neuron, 48, 1011-1023. 
[43]  Dunwiddie,  T.V.  (1999)  Adenosine  and  suppression  of  seizures. 
Adv. Neurol., 79, 1001-1010. 
[44]  Dunwiddie, T.V.,  Diao, L.H., Proctor,  W.R. (1997) Adenine nu-
cleotides undergo rapid, quantitative conversion to adenosine in the 
extracellular  space  in  rat  hippocampus.  J.  Neurosci.,  17,  7673-
7682. 
[45]  Dunwiddie, T.V., Masino, S.A. (2001) The role and regulation of 
adenosine in the central nervous system. Annu. Rev. Neurosci., 24, 
31-55. 
[46]  During, M.J., Spencer, D.D. (1993) Adenosine: a potential mediator of 
seizure arrest and postictal refractoriness. Ann. Neurol., 32, 618-624. 
[47]  Dworak,  M.,  Diel,  P.,  Voss,  S.,  Hollmann,  W.,  Strüder,  H.K. 
(2007) Intense exercise increases adenosine concentrations in rat 
brain:  implications  for  a  homeostatic  sleep  drive.  Neuroscience, 
150, 789-795. 
[48]  Eagles,  D.A.,  Chapman,  G.B.  (2007)  A  light-  and  electron-
microscope study of hepatocytes of rats fed different diets. C. R. 
Biol., 330, 62-70. 
[49]  Edelson,  S.M.,  Edelson,  M.G.,  Kerr,  D.C.,  Grandin,  T.  (1999) 
Behavioral and physiological effects of deep pressure on children 
with autism: a pilot study evaluating the efficacy of Grandin's Hug 
Machine. Am. J. Occup. Ther., 53, 145-152. 
[50]  Eisenach, J.C., Rauck, R.L., Curry, R. (2003) Intrathecal, but not 
intravenous  adenosine  reduces  allodynia  in  patients  with  neuro-
pathic pain. Pain, 105, 65-70. 
[51]  Elzein, E., Zablocki, J. (2008) A1 adenosine receptor agonists and 
their  potential  therapeutic  applications.  Expert  Opin.  Investig. 
Drugs, 17, 1901-1910. 
[52]  Etherington, L.A., Patterson, G.E., Meechan, L., Boison, D., Irving, 
A.J., Dale, N.,  Frenguelli, B. (2008) Astrocytic adenosine kinase 
regulates basal synaptic adenosine levels and seizure activity but 
not activity-dependent adenosine release in the hippocampus. Neu-
ropharmacology, 56, 429-437. 
[53]  Evangeliou,  A.,  Vlachonikolis,  I.,  Mihailidou,  H.,  Spilioti,  M., 
Skarpalezou, A., Makaronas, N., Prokopiou, A., Christodoulou, P., 
Liapi-Adamidou,  G.,  Helidonis,  E.,  Sbyrakis,  S.,  Smeitink,  J. 
(2003) Application of a ketogenic diet in children with autistic be-
havior: pilot study. J. Child Neurol., 18, 113-118. 
[54]  Ferré, S., Agnati, L.F., Ciruela, F., Lluis, C., Woods, A.S., Fuxe, 
K.,  Franco,  R.  (2007)  Neurotransmitter  receptor  heteromers  and 
their integrative role in 'local modules': The striatal spine module. 
Brain Res. Rev., 55, 55-67.  
[55]  Fowler, J.C. (1989) Adenosine antagonists delay hypoxia-induced 
depression of neuronal activity in hippocampal brain slice. Brain 
Res., 490, 378-384. 
[56]  Fowler,  J.C.  (1990)  Adenosine  antagonists  alter  the  synaptic  re-
sponse to in vitro ischemia in the rat hippocampus. Brain Res., 509, 
331-334. 
[57]  Fowler, J.C. (1993) Purine release and inhibition of synaptic trans-
mission  during  hypoxia  and  hypoglycemia  in  rat  hippocampal 
slices. Neurosci. Lett., 157, 83-86. 
[58]  Fredholm, B.B. (1995) Purinoceptors in the nervous system. Phar-
macol. Toxicol., 76, 228-239. 
[59]  Fredholm, B.B. (2007) Adenosine, an endogenous distress signal, 
modulates tissue damage and repair. Cell Death Differ., 14, 1315-
1323. 
[60]  Fredholm, B.B., Bättig, K., Holmén, J., Nehlig, A., Zvartau, E.E. 
(1999) Actions of caffeine in the brain with special reference to 
factors that contribute to its widespread use. Pharmacol. Rev., 51, 
83-133. 
[61]  Fredholm, B.B., Jonzon, B., Lindstrom, K. (1983) Adenosine re-
ceptor mediated increases and decreases in cyclic AMP in hippo-
campal  slices  treated  with  forskolin.  Acta  Physiol.  Scand.,  117, 
461-463. 
[62]  Freeman, J.M., Vining, E.P., Pillas, D.J., Pyzik, P.L., Casey, J.C., 
Kelly, L.M. (1998) The efficacy of the ketogenic diet-1998: a pro-
spective evaluation of intervention in 150 children. Pediatrics, 102, 
1358-1363. 
[63]  Frenguelli, B.G., Llaudet, E., Dale, N. (2003) High-resolution real-
time  recording  with  microelectrode  biosensors  reveals  novel  as-
pects  of  adenosine  release  during  hypoxia  in  rat  hippocampal 
slices. J. Neurochem., 86, 1506-1515. 
[64]  Frenguelli, B.G., Wigmore, G., Llaudet, E., Dale, N. (2007) Tem-
poral and mechanistic dissociation of ATP and adenosine release 
during ischaemia in the mammalian hippocampus. J. Neurochem., 
101, 1400-1413. 
[65]  Fukao, T., Lopaschuk, G.D., Mitchell, G.A. (2004) Pathways and 
control of ketone body metabolism: on the fringe of lipid metabo-
lism. Prostaglandins Leukot. Essent. Fatty Acids, 70, 243-251. 
[66]  Fuxe, K., Ferré, S., Genedani, S., Franco, R., Agnati, L.F. (2007) 
Adenosine  receptor-dopamine  receptor  interactions  in  the  basal 
ganglia and their relevance for brain function. Physiol. Behav., 92, 
210-217. 
[67]  Gabriel, A., Klussmann, F.W., Igelmund, P. (1998) Rapid tempera-
ture  changes  induce  adenosine-mediated  depression  of  synaptic 
transmission in hippocampal slices from rats (non-hibernators) but 
not in slices from golden hamsters (hibernators). Neuroscience, 86, 
67-77. 
[68]  Gallos, G., Ruyle, T.D., Emala, C.W., Lee, H.T. (2005) A1 adeno-
sine receptor knockout mice exhibit increased mortality, renal dys-
function,  and  hepatic  injury  in  murine  septic  peritonitis.  Am.  J. 
Physiol. Renal Physiol., 289, F369-F376. 
[69]  Garriga-Canut, M., Schoenike, B., Qazi, R., Bergendahl, K., Daley, 
T.J., Pfender, R.M., Morrison, J.F., Ockuly, J., Stafstrom, C., Su-
tula,  T.,  Roopra,  A.  (2006)  2-Deoxy-D-glucose  reduces  epilepsy 
progression  by  NRSF-CtBP-dependent  metabolic  regulation  of 
chromatin structure. Nat. Neurosci., 9, 1382-1387. 
[70]  Gasior, M., Rogawski, M.A., Hartman, A.L. (2006) Neuroprotec-
tive  and  disease-modifying  effects  of  the  ketogenic  diet.  Behav. 
Pharmacol., 17, 431-439. 
[71]  Gianfriddo,  M.,  Corsi,  C.,  Melani,  A.,  Pèzzola,  A.,  Reggio,  R., 
Popoli,  P.,  Pedata,  F.  (2003)  Adenosine  A(2A)  antagonism  in-
creases striatal glutamate outflow in the quinolinic acid rat model 
of Huntington's disease. Brain Res., 979, 225-229. 
[72]  Godbout,  R.,  Bergeron,  C.,  Limoges,  E.,  Stip,  E.,  Mottron,  L. 
(2000) A laboratory study of sleep in Asperger's syndrome. Neu-
roreport, 11, 127-130. 
[73]  Goodman, R.R., Snyder, S.H. (1982) Autoradiographic localization 
of adenosine receptors in rat brain using [
3H]cyclohexyladenosine. 
J. Neurosci., 2, 1230-1241. 
[74]  Gouder, N., Fritschy, J.-M., Boison, D. (2003) Seizure suppression 
by adenosine A1 receptor activation in a mouse model of pharma-
coresistant epilepsy. Epilepsia, 44, 877-885. 
[75]  Gouder, N., Scheurer, L., Fritschy, J.M., Boison, D. (2004) Over-
expression of adenosine kinase in epileptic hippocampus contrib-
utes to epileptogenesis. J. Neurosci., 24, 692-701. 
[76]  Gourine, A., Bondar, S.I., Spyer, K.M., Gourine, A.V. (2008) Re-
lease of ATP and glutamate in the nucleus tractus solitarii mediate 
pulmonary  stretch  receptor  (Breuer-Hering)  reflex  pathway.  J. 
Physiol., 586, 3963-3978. 
[77]  Gourine, A.V., Llaudet, E., Dale, N., Spyer, K.M. (2005) ATP is a 
mediator of chemosensory transduction in the central nervous sys-
tem. Nature, 436, 108-111. 266    Current Neuropharmacology, 2009, Vol. 7, No. 3  Masino et al. 
[78]  Grandin, T., Scariano, M.M. (1996) Emergence: Labeled Autistic. 
Warner Books: New York. 
[79]  Guieu, R., Couraud, F., Pouget, J., Sampieri, F., Bechis, G., Ro-
chat, H. (1996) Adenosine and the nervous system: clinical impli-
cations. Clin. Neuropharmacol., 19, 459-474. 
[80]  Haas, R.H., Rice, M.A., Tauner, D.A., Merritt, T.A. (1986) Thera-
peutic effects of a ketogenic diet in Rett syndrome. Am. J. Med. 
Genet. Suppl., 1, 225-246. 
[81]  Haces,  M.L.,  Hernández-Fonseca,  K.,  Medina-Campos,  O.N., 
Montiel, T., Pedraza-Chaverri, J., Massieu, L. (2008) Antioxidant 
capacity contributes to protection of ketone bodies against oxida-
tive damage induced during hypoglycemic conditions. Exp. Neu-
rol., 211, 85-96. 
[82]  Halassa,  M.M.,  Florian,  C.,  Fellin,  T.,  Munoz,  J.R.,  Lee,  S.Y., 
Abel, T., Haydon, P.G., Frank, M.G. (2009) Astrocytic modulation 
of  sleep  homeostasis  and  cognitive  consequences  of  sleep  loss. 
Neuron, 61, 213-219. 
[83]  Hallböök,  T.,  Lundgren,  J.,  Rosén,  I.  (2007)  Ketogenic  diet  im-
proves  sleep  quality  in  children  with  therapy-resistant  epilepsy. 
Epilepsia, 48, 59-65. 
[84]  Herrero Matteo, L.M., Ros Die, E., Sanchez Fernandes-Bravo, J. 
(1977) [Changes in the muscular pH and other parameters of tissue 
hypoxia  during  prolonged  and  intense  exercise]. Angiología,  29, 
118-134. 
[85]  Higdon, J.V., Frei, B. (2006) Coffee and health: a review of recent 
human research. Crit. Rev. Food Sci. Nutr., 46, 101-123. 
[86]  Hill,  C.M.,  Hogan,  A.M.,  Karmiloff-Smith,  A.  (2007)  To  sleep, 
perchance to enrich learning? Arch. Dis. Child., 92, 637-643. 
[87]  Hornig, M., Lipkin, W.I. (2001) Infectious and immune factors in 
the pathogenesis of neurodevelopmental disorders: epidemiology, 
hypotheses, and animal models. Ment. Retard. Dev. Disabil. Res. 
Rev., 7, 200-210. 
[88]  Huang,  Z.L.,  Qu,  W.M.,  Eguchi,  N.,  Chen,  J.F.,  Schwarzschild, 
M.A., Fredholm, B.B., Urade, Y., Hayaishi, O. (2005) Adenosine 
A2A, but not A1, receptors mediate the arousal effect of caffeine. 
Nat. Neurosci., 8, 858-859. 
[89]  Huber,  A.,  Padrun,  V.,  Déglon,  N.,  Aebischer,  P.,  Möhler,  H., 
Boison, D. (2001) Grafts of adenosine-releasing cells suppress sei-
zures in kindling epilepsy. Proc. Natl. Acad. Sci. USA, 98, 7611-
7616. 
[90]  Johansson,  B.,  Halldner,  L.,  Dunwiddie,  T.V.,  Masino,  S.A., 
Poelchen,  W.,  Giménez-Llort,  L.,  Escorihuela,  L.M.,  Fernéndez-
Teruel, A., Wiesenfeld-Hallin, Z., Xu, X.J., Hårdemark, A., Bet-
scholtz,  C.,  Herlenius,  E.,  Fredholm,  B.B.  (2001)  Hyperalgesia, 
anxiety, and decreased hypoxic neuroprotection in mice lacking the 
adenosine A1 receptor. Proc. Natl. Acad. Sci. USA, 98, 9407-9412. 
[91]  Jyonouchi, H., Sun, S., Le, H. (2001) Proinflammatory and regula-
tory cytokine production associated with innate and adaptive im-
mune responses in children with autism spectrum disorders and de-
velopmental regression. J. Neuroimmunol., 120, 170-179. 
[92]  Kafka, S.H., Corbett, R. (1996) Selective adenosine A 2A receptor 
dopamine  D  2  receptor  interactions  in  animal  models  of  schizo-
phrenia. Eur. J. Pharmacol., 295, 147-154. 
[93]  Kaku, T., Jiang, M.H., Hada, J., Morimoto, K., Hayashi, Y. (2001) 
Sodium nitroprusside-induced seizures and adenosine release in rat 
hippocampus. Eur. J. Pharmacol., 413, 199-205. 
[94]  Kalinchuk,  A.V.,  McCarley,  R.W.,  Stenberg,  D.,  Porkka-
Heiskanen,  T.,  Basheer,  R.  (2008)  The  role of  cholinergic  basal 
forebrain  neurons  in  adenosine-mediated  homeostatic  control  of 
sleep:  lessons  from  192  IgG-saporin  lesions. Neuroscience,  157, 
238-253. 
[95]  Kashiwaya,  Y.,  Sato,  K.,  Tsuchiya,  N.,  Thomas,  S.,  Fell,  D.A., 
Veech, R.L., Passonneau, J.V. (1994) Control of glucose utilization 
in working perfused rat heart. J. Biol. Chem., 269, 25502-25514. 
[96]  Kawamura, M., Jr., Masino, S.A. (2008) Purinergic autocrine regu-
lation of CA3 pyramidal neurons: activation of adenosine A1 recep-
tors in the rat hippocampus. Soc. Neurosci. Abstr., 825.26. 
[97]  Kebabian, J.W., Calne, D.B. (1979) Multiple receptors for dopa-
mine. Nature, 277, 93-96. 
[98]  Kern, L., Koegel, R.L., Dunlap, G. (1984) The influence of vigor-
ous  versus  mild  exercise  on  autistic  stereotyped  behaviors.  J. 
Autism Dev. Disord., 14, 57-67. 
[99]  Kim, D., Rho, J. (2007) Ketone bodies potect against impairment 
of synaptic transmission in rat hippocampal slices by mitochondrial 
respiratory inhibitors. Soc. Neurosci. Abstr., 786.713. 
[100]  Klotz, K.N. (2000) Adenosine receptors and their ligands. Naunyn-
Schmeidebergs Arch. Pharmacol., 362, 382-391. 
[101]  Knapp, C.M., Foye, M.M., Cottam, N., Ciraulo, D.A., Kornetsky, 
C. (2001) Adenosine agonists CGS 21680 and NECA inhibit the 
initiation of cocaine self-administration. Pharmacol. Biochem. Be-
hav., 68, 797-803. 
[102]  Korde,  A.S.,  Pettigrew,  L.C.,  Craddock,  S.D.,  Maragos,  W.F. 
(2005)  The  mitochondrial  uncoupler  2,4-dinitrophenol  attenuates 
tissue damage and improves mitochondrial homeostasis following 
transient focal cerebral ischemia. J. Neurochem., 94, 1676-1684. 
[103]  Kossoff,  E.H.,  Dorward,  J.L.  (2008)  The  modified  Atkins  diet. 
Epilepsia, 49 (Suppl 8), 37-41. 
[104]  Kossoff,  E.H.,  Krauss,  G.L.,  McGrogan,  J.R.,  Freeman,  J.M. 
(2003) Efficacy of the Atkins diet as therapy for intractable epi-
lepsy. Neurology, 61, 1789-1791. 
[105]  Kotagal, P., Yardi, N. (2008) The relationship between sleep and 
epilepsy. Semin. Pediatr. Neurol., 15, 42-49. 
[106]  Kwan, R.M., Thomas, S., Mir, M.A. (1986) Effects of a low carbo-
hydrate isoenergetic diet on sleep behavior and pulmonary func-
tions in healthy female adult humans. J. Nutr., 116, 2393-2402. 
[107]  Lara,  D.R.,  Brunstein,  M.G.,  Ghisolfi,  E.S.,  Lobato,  M.I., 
Belmonte-de-Abreu, P., Souza, D.O. (2001) Allopurinol augmenta-
tion for poorly responsive schizophrenia. Int. Clin. Psychopharma-
col., 16, 235-237. 
[108]  Latini, S., Corsi, C.,  Pedata, F., Pepeu, G. (1995) The source of 
brain adenosine outflow during ischemia and electrical stimulation. 
Neurochem. Int., 27, 239-244. 
[109]  Latini, S., Pedata, F. (2001) Adenosine in the central nervous sys-
tem: release mechanisms and extracellular concentrations. J. Neu-
rochem., 79, 463-484. 
[110]  Lee, H.T., Xu, H., Nasr, S.H., Schnermann, J., Emala, C.W. (2004) 
A1 adenosine receptor knockout mice exhibit increased renal injury 
following ischemia and reperfusion. Am. J. Physiol. Renal Physiol., 
286, F298-F306. 
[111]  Lee, J., Bruce-Keller, A.J., Kruman, Y., Chan, S.L., Mattson, M.P. 
(1999) 2-Deoxy-D-glucose  protects  hippocampal  neurons  against 
excitotoxic and oxidative injury: evidence for the involvement of 
stress proteins. J. Neurosci. Res., 57, 48-61. 
[112]  Lee, Y.-W., Yaksh, T.L. (1996) Pharmacology of the spinal adeno-
sine receptor which mediates the antiallodynic action of intrathecal 
adenosine agonists. J. Pharmacol. Exp. Ther., 277, 1642-1648. 
[113]  Listos, J., Talarek, S., Fidecka, S. (2008) Involvement of adenosine 
receptor agonists on the development of hypersensitivity to acute 
dose of morphine during morphine withdrawal period. Pharmacol. 
Rep., 60, 679-685. 
[114]  Lloyd,  H.G.,  Lindström,  K.,  Fredholm,  B.B.  (1993)  Intracellular 
formation  and  release  of  adenosine  from  rat  hippocampal  slices 
evoked by electrical stimulation or energy depletion. Neurochem. 
Int., 23, 173-185. 
[115]  LoVerme, J., Fu, J., Astarita, G., La Rana, G., Russo, R., Calig-
nano, A., Piomelli, D. (2005) The nuclear receptor peroxisome pro-
liferator-activated  receptor-alpha  mediates  the  anti-inflammatory 
actions of palmitoylethanolamide. Mol. Pharmacol., 67, 15-19. 
[116]  Ma, T.C., Buescher, J.L., Oatis, B., Funk, J.A., Nash, A.J., Carrier, 
R.L., Hoyt, K.R. (2007) Metformin therapy in a transgenic mouse 
model of Huntington's disease. Neurosci. Lett., 411, 98-103. 
[117]  Maalouf,  M.,  Sullivan,  P.G.,  Davis,  L.,  Kim,  D.Y.,  Rho,  J.M. 
(2007) Ketones inhibit mitochondrial production of reactive oxy-
gen  species production  following  glutamate  excitotoxicity  by  in-
creasing NADH oxidation. Neuroscience, 145, 256-264. 
[118]  Malow, B.A. (2004) Sleep disorders, epilepsy, and autism. Ment. 
Retard. Dev. Disabil. Res. Rev., 10, 122-125. 
[119]  Manzoni, O.J., Manabe, T., Nicoll, R.A. (1994) Release of adeno-
sine  by  activation  of  NMDA  receptors  in  the  hippocampus. Sci-
ence, 265, 2098-2101. 
[120]  Marie, S., Race, V., Nassogne, M.C., Vincent, M.F., Van den Ber-
ghe, G. (2002) Mutation of a nuclear respiratory factor 2 binding 
site in the 5' untranslated region of the ADSL gene in three patients 
with adenylosuccinate lyase deficiency. Am. J. Hum. Genet., 71, 
14-21. 
[121]  Marsh, J., Mukherjee, P., Seyfried, T.N. (2008) Drug/diet synergy 
for managing malignant astrocytoma in mice: 2-deoxy-D-glucose 
and the restricted ketogenic diet. Nutr. Metab. (Lond.), 5, 33. 
[122]  Martin, B., Golden, E., Carlson, O.D., Pistell, P., Zhou, J., Kim, 
W., Frank, B.P., Thomas, S., Chadwick, W.A., Greig, N.H., Bates, Adenosine, Ketogenic Diet and Epilepsy  Current Neuropharmacology, 2009, Vol. 7, No. 3    267 
G.P.,  Sathasivam, K., Bernier,  M.,  Maudsley, S., Mattson, M.P., 
Egan, J.M. (2009) Exendin-4 improves glycemic control, amelio-
rates brain and pancreatic pathologies, and extends survival in a 
mouse model of Huntington's disease. Diabetes, 58, 318-328. 
[123]  Martín, E.D., Fernández, M., Perea, G., Pascual, O., Haydon, P.G., 
Araque, A., Ceña, V. (2007) Adenosine released by astrocytes con-
tributes  to  hypoxia-induced  modulation of  synaptic  transmission. 
Glia, 55, 36-45. 
[124]  Masino,  S.A.,  Dunwiddie,  T.V.  (1999)  Temperature-dependent 
modulation of excitatory transmission in hippocampal slices is me-
diated by extracellular adenosine. J. Neurosci., 19, 1932-1939. 
[125]  Masino,  S.A.,  Geiger,  J.D.  (2008)  Are  purines  mediators  of  the 
anticonvulsant/neuroprotective  effects  of  ketogenic  diets? Trends 
Neurosci., 31, 273-278.  
[126]  Masino, S.A., Geiger, J.D. (2009) The ketogenic diet and epilepsy: 
Is adenosine the missing link? Epilepsia, 50, 332-333.  
[127]  Masino,  S.A.,  Gockel,  J.A.,  Wasser,  C.A.,  Pomeroy,  L.T., 
Wagener, J.F., Gawryluk, J.W., Geiger, J.D. (2007) The relation-
ship among ATP, adenosine and a ketogenic diet. Soc. Neurosci. 
Abstr., 595.512. 
[128]  Masino, S.A., Latini, S., Bordoni, F., Pedata, F., Dunwiddie, T.V. 
(2001) Changes in hippocampal adenosine efflux, ATP levels, and 
synaptic transmission induced by increased temperature. Synapse, 
41, 58-64. 
[129]  Masino,  S.A.,  Mesches,  M.H.,  Bickford,  P.C.,  Dunwiddie,  T.V. 
(1999) Acute peroxide treatment of rat hippocampal slices induced 
adenosine-mediated  inhibition  of  excitatory  transmission  in  area 
CA1. Neurosci. Lett., 274, 91-94. 
[130]  Melani,  A.,  Corsi,  C.,  Giménez-Llort,  L.,  Martínez,  E.,  Ogren, 
S.O., Pedata, F., Ferré, S. (1999) Effect of N-methyl-D-aspartate on 
motor activity and in vivo adenosine striatal outflow in the rat. Eur. 
J. Pharmacol., 385, 15-19. 
[131]  Minor, T.R., Rowe, M.K., Soames Job, R.F., Ferguson, E.C. (2001) 
Escape deficits induced by inescapable shock and metabolic stress 
are reversed by adenosine receptor antagonists. Behav. Brain Res., 
120, 203-212. 
[132]  Mitchell,  J.B.,  Lupica,  C.R.,  Dunwiddie,  T.V.  (1993)  Activity-
dependent release of endogenous adenosine modulates synaptic re-
sponses in the rat hippocampus. J. Neurosci., 13, 3439-3447. 
[133]  Murillo-Rodriguez, E., Liu, M., Blanco-Centurion, C., Shiromani, 
P.J. (2008) Effects of hypocretin (orexin) neuronal loss on sleep 
and extracellular adenosine levels in the rat basal forebrain. Eur. J. 
Neurosci., 28, 1191-1198. 
[134]  Nakazawa, M., Kodama, S., Matsuo, T. (1983) Effects of ketogenic 
diet on electroconvulsive threshold and brain contents of adenosine 
nucleotides. Brain Dev., 5, 375-380. 
[135]  Neal, E.G., Chaffe, H., Schwartz, R.H., Lawson, M.S., Edwards, 
N.,  Fitzsimmons,  G.,  Whitney,  A.,  Cross,  J.H.  (2008)  The  keto-
genic diet for the treatment of childhood epilepsy: a randomised 
controlled trial. Lancet Neurol., 7, 500-506. 
[136]  Nehlig, A., Daval, J.L., Debry, G. (1992) Caffeine and the central 
nervous system: mechanisms of action, biochemical, metabolic and 
psychostimulant effects. Brain Res. Brain Res. Rev., 17, 139-170. 
[137]  Nemeth,  P.M.,  Rosser,  B.W.,  Choksi,  R.M.,  Norris,  B.J.,  Baker, 
K.M. (1992) Metabolic response to a high-fat diet in neonatal and 
adult rat muscle. Am. J. Physiol. Cell Physiol., 262, C282-C286. 
[138]  Newby,  A.C.  (1984)  Adenosine  and  the  concept  of  "retaliatory 
metabolites." Trends Biochem. Sci., 9, 42-44. 
[139]  Newcomer, J.W. (2004) Metabolic risk during antipsychotic treat-
ment. Clin. Ther., 26, 1936-1946. 
[140]  Niglio, T., Popoli, P., Caporali, M.G., Scotti de Carolis, A. (1988) 
Antiepileptic  effects  of  N6-L-phenylisopropyladenosine  (L-PIA) 
on  penicillin-induced  epileptogenic  focus  in  rabbits.  Pharmacol. 
Res. Commun., 20, 561-572. 
[141]  Noh, H.S., Lee, H.P., Kim, D.W., Kang, S.S., Cho, G.J., Rho, J.M., 
Choi, W.S. (2004) A cDNA microarray analysis of gene expression 
profiles in rat hippocampus following a ketogenic diet. Mol. Brain 
Res., 129, 80-87. 
[142]  Nyhan,  W.L.,  James,  J.A.,  Teberg,  A.J.,  Sweetman,  L.,  Nelson, 
L.G. (1969) A new disorder of purine metabolism with behavioral 
manifestations. J. Pediatr., 74, 20-27. 
[143]  Nylen,  K.,  Velazquez,  J.L.,  Sayed,  V.,  Gibson, K.M.,  Burnham, 
W.M., Snead, O.C., 3rd (2009) The effects of a ketogenic diet on 
ATP concentrations and the number of hippocampal mitochondria 
in Aldh5a1(-/-) mice. Biochim. Biophys. Acta, in press. 
[144]  O'Neill, M.F. (2005) Study focuses in on potential cause of antip-
sychotic-induced diabetes. Drug News Perspect., 18, 481-482. 
[145]  Orford, M.R., Saggerson, E.D. (1996) A low-Km 5'-nucleotidase 
from  rat  brain  cytosolic  fraction:  purification,  kinetic  properties, 
and description of regulation by a novel factor that increases sensi-
tivity to inhibition by ATP and ADP. J. Neurochem., 67, 795-804. 
[146]  Otsuguro,  K.,  Yamaji,  Y.,  Ban,  M.,  Ohta,  T.,  Ito,  S.  (2006)  In-
volvement of adenosine in depression of synaptic transmission dur-
ing hypercapnia in isolated spinal cord of neonatal rats. J. Physiol., 
574, 835-847. 
[147]  Owen, O.E., Morgan, A.P., Kemp, H.G., Sullivan, J.M., Herrera, 
M.G., Cahill, G.F., Jr. (1967) Brain metabolism during fasting. J. 
Clin. Invest., 46, 1589-1595. 
[148]  Pacheco, A., Easterling, W.S., Pryer, M.W. (1965) A pilot study of 
the ketogenic diet in schizophrenia. Am. J. Psychiatry, 121, 1110-
1111. 
[149]  Page, T., Coleman, M. (2000) Purine metabolism abnormalities in a 
hyperuricosuric subclass of autism. Biochim. Biophys. Acta, 1500, 
291-296. 
[150]  Page, T., Moseley, C. (2002) Metabolic treatment of hyperurico-
suric autism. Prog. Neuropsychopharmacol. Biol. Psychiatry, 26, 
397-400. 
[151]  Pan, J.W., Bebin, E.M., Chu, W.J., Hetherington, H.P. (1999) Ke-
tosis and epilepsy: 
31P spectroscopic imaging at 4.1 T. Epilepsia, 
40, 703-707. 
[152]  Pandya,  J.D.,  Pauly,  J.R.,  Nukala,  V.N.,  Sebastian,  A.H.,  Day, 
K.M.,  Korde,  A.S.,  Maragos,  W.F.,  Hall,  E.D.,  Sullivan,  P.G. 
(2007) Post-injury administration of mitochondrial uncouplers in-
creases tissue sparing and improves behavioral outcome following 
traumatic brain injury in rodents. J. Neurotrauma, 24, 798-811. 
[153]  Panico, L.R., Ríos, V.G., Demartini, M.G., Carniello, M.A. (2000) 
[The electroencephalographic evolution of a group of patients on a 
ketonic diet]. Rev. Neurol., 30, 8-15. 
[154]  Parkinson, F.E., Xiong, W. (2004) Stimulus- and cell-type-specific 
release of purines in cultured rat forebrain astrocytes and neurons. 
J. Neurochem., 88, 1305-1312. 
[155]  Parkinson, F.E., Xiong, W., Zamzow, C.R. (2005) Astrocytes and 
neurons:  different  roles  in  regulating  adenosine  levels.  Neurol. 
Res., 27, 153-160. 
[156]  Pascual, O., Casper, K.B., Kubera, C., Zhang, J., Revilla-Sanchez, 
R., Sul, J.Y., Takano, H., Moss, S.J., McCarthy, K., Haydon, P.G. 
(2005)  Astrocytic  purinergic  signaling  coordinates  synaptic  net-
works. Science, 310, 113-116. 
[157]  Pedata, F., Pazzagli, M., Tilli, S., Pepeu, G. (1990) Regional differ-
ences in the electrically stimulated release of endogenous and ra-
dioactive  adenosine  and purine derivatives  from  rat brain  slices. 
Naunyn Schmeidebergs Arch. Pharmacol., 342, 447-453. 
[158]  Peters, S.J., St. Amand, T.A., Howlett, R.A., Heigenhauser, G.J.F., 
Spriet, L.L. (1998) Human skeletal muscle pyruvate dehydrogenase 
kinase  activity  increases  after  a  low-carbohydrate  diet.  Am.  J. 
Physiol. Endocrinol. Metab., 275, E980-E986. 
[159]  Phillips, F., Chen, C.N., Crisp, A.H., Koval, J., McGuinness, B., 
Kalucy,  R.S.,  Kalucy,  E.C.,  Lacey,  J.H.  (1975)  Isocaloric  diet 
changes and electroencephalographic sleep. Lancet, 2, 723-725. 
[160]  Plunet, W.T., Streijger, F., Lam, C.K., Lee, J.H., Liu, J., Tetzlaff, 
W. (2008) Dietary restriction started after spinal cord injury im-
proves functional recovery. Exp. Neurol., 213, 28-35. 
[161]  Porkka-Heiskanen,  T.,  Strecker,  R.E.,  McCarley,  R.W.  (2000) 
Brain  site-specificity  of  extracellular  adenosine  concentration 
changes during sleep deprivation and spontaneous sleep: an in vivo 
microdialysis study. Neuroscience, 99, 507-517. 
[162]  Porkka-Heiskanen, T., Strecker, R.E., Thakkar, M., Bjorkum, A.A., 
Greene, R.W., McCarley, R.W. (1997) Adenosine: a mediator of 
the sleep-inducing effects of prolonged wakefulness. Science, 276, 
1265-1268. 
[163]  Portenoy, R.K., Foley, K.M., Inturrisi, C.E. (1990) The nature of 
opioid  responsiveness  and  its  implications  for  neuropathic  pain: 
new hypotheses derived from studies of opioid infusions. Pain, 43, 
273-286. 
[164]  Qin,  P.,  Xu,  H.,  Laursen,  T.M.,  Vestergaard,  M.,  Mortensen,  P.B. 
(2005) Risk for schizophrenia and schizophrenia-like psychosis among 
patients with epilepsy: population based cohort study. BMJ, 331, 23. 
[165]  Radulovacki,  M.,  Miletich,  R.S.,  Green,  R.D.  (1982)  N6  (L-
phenylisopropyl)  adenosine  (L-PHA)  increases  slow-wave  sleep 
(S2) and decreases wakefulness in rats. Brain Res., 246, 178-180. 268    Current Neuropharmacology, 2009, Vol. 7, No. 3  Masino et al. 
[166]  Rainnie,  D.G.,  Grunze,  H.C.,  McCarley,  R.W.,  Greene,  R.W. 
(1994) Adenosine inhibition of mesopontine cholinergic neurons: 
implications for EEG arousal. Science, 263, 689-692. 
[167]  Rho, J.M., Sarnat, H.B., Sullivan, P.G., Robbins, C.A., Kim, D.W. 
(2004)  Lack  of  long-term  histopathologic  changes  in  brain  and 
skeletal muscle of mice treated with a ketogenic diet. J. Child Neu-
rol., 19, 555-557. 
[168]  Rogawski, M.A. (2006) Diverse mechanisms of antiepileptic drugs 
in the development pipeline. Epilepsy Res., 69, 273-294. 
[169]  Rosin, D.L., Hettinger, B.D., Lee, A., Linden, J. (2003) Anatomy 
of adenosine A2A receptors in brain: morphological substrates for 
integration of striatal function. Neurology, 61, S12-18. 
[170]  Sala-Newby, G.B., Skladanowski, A.C., Newby, A.C. (1999) The 
mechanism of adenosine formation in cells. Cloning of cytosolic 5'-
nucleotidase-I. J. Biol. Chem., 274, 17789-17793. 
[171]  Sampath, A., Kossoff, E.H., Furth, S.L., Pyzik, P.L., Vining, E.P. 
(2007) Kidney stones and the ketogenic diet: risk factors and pre-
vention. J. Child. Neurol., 22, 375-378.  
[172]  Saransaari,  P.,  Oja,  S.S.  (2003)  Enhanced  release  of  adenosine 
under cell-damaging conditions in the developing and adult mouse 
hippocampus. Neurochem. Res., 28, 1409-1417. 
[173]  Sato, K., Kashiwaya, Y., Keon, C.A.,  Tsuchiya, N., King,  M.T., 
Radda, G.K., Chance, B., Clarke, K., Veech, R.L. (1995) Insulin, 
ketone  bodies,  and  mitochondrial  energy  transfer.  FASEB  J.,  9, 
651-658. 
[174]  Satoh, S., Matsumura, H., Suzuki, F., Hayaishi, O. (1996) Promo-
tion of sleep mediated by the A2a-adenosine receptor and possible 
involvement of this receptor in the sleep induced by prostaglandin 
D2 in rats. Proc. Natl. Acad. Sci. USA, 93, 5980-5984. 
[175]  Schubert, P. (1988) Physiological modulation by adenosine: selec-
tive  blockade  of  A1-receptors  with  DPCPX  enhances  stimulus 
train-evoked neuronal Ca influx in rat hippocampal slices. Brain 
Res., 458, 162-165. 
[176]  Semba, K., White, T.D. (1997) M3 muscarinic receptor-mediated 
enhancement  of  NMDA-evoked  adenosine  release  in  rat  cortical 
slices in vitro. J. Neurochem., 69, 1066-1072. 
[177]  Seyfried, T.N., Mukherjee, P. (2005) Targeting energy metabolism 
in brain cancer: review and hypothesis. Nutr. Metab., 2, 30. 
[178]  Simonoff, E., Pickles, A., Charman, T., Chandler, S., Loucas, T., 
Baird, G. (2008) Psychiatric disorders in children with autism spec-
trum disorders: prevalence, comorbidity, and associated factors in a 
population-derived sample. J. Am. Acad. Child Adolesc. Psychia-
try, 47, 921-929. 
[179]  Smith, M., Hopkins, D., Peveler, R.C., Holt, R.I., Woodward, M., 
Ismail,  K.  (2008)  First-  v.  second-generation  antipsychotics  and 
risk  for  diabetes  in  schizophrenia:  systematic  review  and  meta-
analysis. Br. J. Psychiatry, 192, 406-411. 
[180]  Sollevi, A. (1997) Adenosine for pain control. Acta Anaesthesiol. 
Scand. Suppl., 110, 135-136. 
[181]  Stafstrom, C.E., Roopra, A., Sutula, T.P. (2008) Seizure suppres-
sion via glycolysis inhibition with 2-deoxy-D-glucose (2DG). Epi-
lepsia, 49(Suppl 8), 97-100. 
[182]  Sullivan,  P.G.,  Rippy,  N.A.,  Dorenbos,  K.,  Concepcion,  R.C., 
Agarwal, A.K., Rho, J.M. (2004) The ketogenic diet increases mi-
tochondrial  uncoupling protein  levels  and activity. Ann.  Neurol., 
55, 576-580. 
[183]  Sun, C.-X., Young, H.W., Molina, J.G., Volmer, J.B., Schnermann, 
J., Blackburn, M.R. (2005) A protective role for the A1 adenosine 
receptor in adenosine-dependent pulmonary injury. J. Clin. Invest., 
115, 35-43. 
[184]  Tierney, E., Nworoko, N.A., Kelley, R.I. (2000) Behavioral pheno-
type  of  RSH/Smith-Lemli-Opitz  syndrome.  Ment.  Retard.  Dev. 
Disabil. Res. Rev., 6, 131-134. 
[185]  Tsutsui,  S.,  Schnermann,  J.,  Noorbakhsh,  F.,  Henry,  S.,  Yong, 
V.W., Winston, B.W., Warren, K., Power, C. (2004) A1 adenosine 
receptor upregulation and activation attenuates neuroinflammation 
and demyelination in a model of multiple sclerosis. J. Neurosci., 
24, 1521-1529. 
[186]  Varma,  H.,  Cheng,  R.,  Voisine,  C.,  Hart,  A.C.,  Stockwell,  B.R. 
(2007) Inhibitors of metabolism rescue cell death in Huntington's 
disease models. Proc. Natl. Acad. Sci. USA, 104, 14525-14530. 
[187]  Veech, R.L. (2004) The therapeutic implications of ketone bodies: 
the effects of ketone bodies in pathological conditions: ketosis, ke-
togenic diet, redox states, insulin resistance, and mitochondrial me-
tabolism. Prostaglandins Leukot. Essent. Fatty Acids, 70, 309-319. 
[188]  Vining,  E.P.,  Freeman,  J.M.,  Ballaban-Gil,  K.,  Camfield,  C.S., 
Camfield, P.R., Holmes, G.L., Shinnar, S., Shuman, R., Trevathan, 
E., Wheless, J.W. (1998) A multicenter study of the efficacy of the 
ketogenic diet. Arch. Neurol., 55, 1433-1437. 
[189]  Virus,  R.M.,  Ticho,  S.,  Pilditch,  M.,  Radulovacki,  M.  (1990)  A 
comparison  of  the  effects  of  caffeine,  8-cyclopentyltheophylline, 
and alloxazine on sleep in rats. Possible roles of central nervous 
system  adenosine  receptors.  Neuropsychopharmacology,  3,  243-
249. 
[190]  Von  Lubitz,  D.K.J.E.,  Beenhakker,  M.,  Lin,  R.C.,  Carter,  M.F., 
Paul, I.A., Bischofberger, N., Jacobson, K.A. (1996) Reduction of 
postischemic brain damage  and  memory deficits  following  treat-
ment  with  the  selective  adenosine  A1  receptor  agonist.  Eur.  J. 
Pharmacol., 302, 43-48. 
[191]  Weerts,  E.M.,  Griffiths,  R.R.  (2003)  The  adenosine  receptor  an-
tagonist CGS15943 reinstates cocaine-seeking behavior and main-
tains  self-administration  in  baboons.  Psychopharmacology,  168, 
155-163. 
[192]  Westman, E.C., Yancy, W.S., Jr., Mavropoulos, J.C., Marquart, M., 
McDuffie, J.R. (2008) The effect of a low-carbohydrate, ketogenic 
diet versus a low-glycemic index diet on glycemic control in type 2 
diabetes mellitus. Nutr. Metab. (Lond.), 5, 36. 
[193]  Whitcomb,  K.,  Lupica,  C.R.,  Rosen,  J.B.,  Berman,  R.F.  (1990) 
Adenosine  involvement  in  postictal  events  in  amygdala-kindled 
rats. Epilepsy Res., 6, 171-179. 
[194]  Wilder,  R.M.  (1921)  The  effects  of  ketonemia  on  the  course  of 
epilepsy. Mayo Clin. Proc., 2, 307-308. 
[195]  Wong, V. (1993) Epilepsy in children with autistic spectrum disor-
der. J. Child Neurol., 8, 316-322. 
[196]  Wu, W.-P., Hao, J.-X., Halldner, L., Lovdahl, C., DeLander, G.E., 
Wiesenfeld-Hallin, Z., Fredholm, B.B., Xu, X.-J. (2005) Increased 
nociceptive  response  in  mice  lacking  the  adenosine  A1  receptor. 
Pain, 113, 395-404. 
[197]  Xu, K., Bastia, E., Schwarzschild, M. (2005) Therapeutic potential 
of  adenosine  A(2A)  receptor  antagonists  in  Parkinson's  disease. 
Pharmacol. Ther., 105, 267-310. 
[198]  Yancy, W.S., Jr., Foy, M., Chalecki, A.M., Vernon, M.C., West-
man, E.C. (2005) A low-carbohydrate, ketogenic diet to treat type 2 
diabetes. Nutr. Metab. (Lond.), 2, 34. 
[199]  Zhang, J.-M., Wang, H.-K., Ye, C.-Q., Ge, W., Chen, Y., Jiang, Z.-
l., Wu, C.-P., Poo, M.-M., Duan, S. (2003) ATP released by astro-
cytes  mediates  glutamatergic  activity-dependent  heterosynaptic 
suppression. Neuron, 40, 971-982. 
[200]  Zhao, Y.T., Tekkök, S., Krnjević, K. (1997) 2-Deoxy-D-glucose-
induced changes in membrane potential, input resistance, and exci-
tatory postsynaptic potentials of CA1 hippocampal neurons. Can. J. 
Physiol. Pharmacol., 75, 368-374. 
[201]  Zhu, P.J., Krnjević, K. (1993) Adenosine release is a major cause 
of  failure  of  synaptic  transmission  during  hypoglycaemia  in  rat 
hippocampal slices. Neurosci. Lett., 155, 128-131. 
[202]  Zhu, P.J., Krnjević, K. (1997) Adenosine release mediates cyanide-
induced  suppression  of  CA1  neuronal  activity.  J.  Neurosci.,  17, 
2355-2364. 
[203]  Ziegler,  D.R.,  Gamaro,  G.D.,  Araújo,  E.,  Bassani,  M.G.,  Perry, 
M.L.S., Dalmaz, C., Gonçalves, C.-A. (2005) Nociception and lo-
comotor activity are increased in ketogenic diet fed rats. Physiol. 
Behav., 84, 421-427. 
 
Received: February 23, 2009  Revised: May 01, 2009  Accepted: May 06, 2009 
 